Replimune Group, Inc.
Clinical-stage biotech developing oncolytic immunotherapies to treat a broad range of cancers.
REPL | NDAQ
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 500 UNICORN PARK, 1801 WOBURN
- Website:
- https://www.replimune.com/
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Replimune Group, Inc. is a clinical-stage biotechnology company focused on developing a new class of oncolytic immunotherapies to treat cancer. The company's mission is to revolutionize cancer treatment by pioneering therapies designed to ignite a powerful, durable, and systemic anti-tumor immune response. Replimune's approach aims to comprehensively activate a tumor-specific immune reaction, with the potential to treat a broad range of cancer types.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Replimune Group, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Replimune Group, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Replimune Group, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
